Cargando…

Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

INTRODUCTION: Lazertinib is an irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Co-administration of TKIs with acid-reducing agents (ARAs) can lead to potential drug–drug interactions, which decreases solubility and absorption of TKIs and is ult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Bomin, Lee, Jungwook, Jang, Hyunwoo, Lee, Nami, Mehta, Jaydeep, Jang, Seong Bok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464755/ https://www.ncbi.nlm.nih.gov/pubmed/35962934 http://dx.doi.org/10.1007/s12325-022-02286-z

Ejemplares similares

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
por: Jang, Seong Bok, et al.
Publicado: (2021)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Lazertinib: on the Way to Its Throne
por: Lee, Jiyun, et al.
Publicado: (2022)

Lazertinib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2023)

Correction to: Lazertinib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
por: Cho, Byoung Chul, et al.
Publicado: (2023)

Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment‐naive patients with advanced EGFR mutation‐positive non‐small cell lung cancer: Protocol of an open‐label, single‐arm phase II trial
por: Lee, Bora, et al.
Publicado: (2023)

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiation therapy (PLATINUM trial)
por: Choi, Juwhan, et al.
Publicado: (2022)

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
por: Fang, Yue, et al.
Publicado: (2023)

Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer
por: Lee, Hyunwoo, et al.
Publicado: (2021)

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo
por: Fan, Yingfang, et al.
Publicado: (2022)

A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation
por: Kim, Siun, et al.
Publicado: (2021)

Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach
por: Jeong, Seung-Hyun, et al.
Publicado: (2021)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats
por: Jeong, Seung-Hyun, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen
por: Jang, Ji-Hun, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
por: Jones, Rhys D.O., et al.
Publicado: (2023)

A Gallium-based Chiral Solvating Agent Enables the Use of (1)H NMR Spectroscopy to Differentiate Chiral Alcohols
por: Jang, Sumin, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects
por: Jeong, Seung-Hyun, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
por: Jeong, Seung-Hyun, et al.
Publicado: (2021)

Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling
por: Jeong, Seung-Hyun, et al.
Publicado: (2023)

Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation
por: Jang, Seung Hun
Publicado: (2014)

Pharmacokinetic Comparison of Epinastine Using Developed Human Plasma Assays
por: Jeong, Seung-Hyun, et al.
Publicado: (2020)

Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study
por: Jang, Ji-Hun, et al.
Publicado: (2020)

Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans
por: Jang, Ji-Hun, et al.
Publicado: (2019)

Pharmacokinetic Changes According to Single or Multiple Oral Administrations of Socheongryong-Tang to Rats: Presented as a Typical Example of Changes in the Pharmacokinetics Following Multiple Exposures to Herbal Medicines
por: Jeong, Seung-Hyun, et al.
Publicado: (2021)

Application of several machine learning algorithms for the prediction of afatinib treatment outcome in advanced‐stage EGFR‐mutated non‐small‐cell lung cancer
por: Kim, Taeyun, et al.
Publicado: (2022)

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
por: Jung, Jin Ah, et al.
Publicado: (2015)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Multicenter real‐world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non‐small cell lung cancer
por: Lee, Su Yeon, et al.
Publicado: (2021)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors
por: Lee, Hyunwoo, et al.
Publicado: (2022)

Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma
por: Jeong, Seung-Hyun, et al.
Publicado: (2021)

EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
por: Nan, Xueli, et al.
Publicado: (2017)

Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study
por: Kim, Taeyun, et al.
Publicado: (2023)

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
por: Lu, Shun, et al.
Publicado: (2021)

Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics
por: Jang, Ji-Hun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tttogg4jikvkgc6l56o04lp33d